Selegilin

Selegilin

Nama sistematis (IUPAC)
(R)-N-metil-N-(1-fenilpropan-2-il)prop-3-in-1-amina
Data klinis
Nama dagang	Eldepryl, Jumex, Zelapar, Emsam, Anipryl, dll[1]
AHFS/Drugs.com	monograph
MedlinePlus	a697046
Data lisensi	US FDA:link
Kat. kehamilan	B2(AU) C(US)
Status hukum	Harus dengan resep dokter (S4) (AU) ℞-only (CA) POM (UK) ℞-only (US)
Rute	Oral,[2][3] bukal,[4][5] transdermal[6][7]
Data farmakokinetik
Bioavailabilitas	Oral: 4–10%[3][8][9] bukal: ~5–8× oral[10][5][11] Transdermal: 75%[7]
Ikatan protein	85–90%[7][6][4]
Metabolisme	Hati, jaringan lain (CYP2B6, CYP2C19, lainnya)[3][12][7][13]
Waktu paruh	Oral: • S (tunggal): 1,2–3,5 jam[3] • S (ganda): 7,7–9,7 jam[3][9] • DMS (tunggal): 2,2–3,8 jam[3] • DMS (ganda): 9,5 jam[3] • L-MA: 14–21 jam[3][5] • L-A: 16–18 jam[3][5] bukal: • S (tunggal): 1,3 jam[4] • S (ganda): 10 jam[4] transdermal: • S: 20 jam[9][6]
Ekskresi	Urin (87%):[14][15][5][3][16] • L-MA: 20–63% • L-A: 9–26% • DMS: 1% • S: 0,01–0,03% Feses: 15%[14][5]
Pengenal
Nomor CAS	14611-51-9 Y 14611-52-0 (HCl)
Kode ATC	N04BD01 QN06AX90
PubChem	CID 26757
Ligan IUPHAR	6639
DrugBank	DB01037
ChemSpider	24930 Y
UNII	2K1V7GP655 Y
KEGG	D03731 Y
ChEBI	CHEBI:9086 Y
ChEMBL	CHEMBL972 Y
Sinonim	L-Deprenil; L-Deprenalin; L-E-250; l-E-250; L-Fenilisopropilmetilpropinilamina; (R)-(–)-N,α-Dimetil-N-2-propinilfenetilamina; (R)-(–)-N-Metil-N-2-propinilfenetilamina; (R)-(–)-N-2-propinilfenetilamina; N-Propargil-L-metamfetamina
Data kimia
Rumus	C13H17N
InChI InChI=1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3/t12-/m1/s1 Y Key:MEZLKOACVSPNER-GFCCVEGCSA-N Y

Selegilin adalah penghambat monoamin oksidase-β (MAO-β) secara ireversibel yang digunakan sebagai terapi tambahan bersama levodopa ataupun sendiri pada penyakit Parkinson tahap lanjut untuk meringankan fenomena wearing off.^[17][18]

1. ^ "Selegiline". Drugs.com. Diarsipkan dari versi asli tanggal 2024-07-03. Diakses tanggal February 7, 2016. 
2. ^ "ELDEPRYL® (Selegiline Hydrochloride) Tablets, USP Label" (PDF). Food and Drug Administration. January 2008. Diakses tanggal 3 July 2024. 
3. ^ ^{a b c d e f g h i j} Mahmood I (August 1997). "Clinical pharmacokinetics and pharmacodynamics of selegiline. An update". Clin Pharmacokinet. 33 (2): 91–102. doi:10.2165/00003088-199733020-00002. PMID 9260033. 
4. ^ ^{a b c d} "ZELAPAR® (Selegiline Hydrochloride) Orally Disintegrating Tablets" (PDF). Food and Drug Administration. July 2021. Diakses tanggal 3 July 2024. 
5. ^ ^{a b c d e f} Poston KL, Waters C (October 2007). "Zydis selegiline in the management of Parkinson's disease". Expert Opin Pharmacother. 8 (15): 2615–2624. doi:10.1517/14656566.8.15.2615. PMID 17931095. 
6. ^ ^{a b c} "EMSAM® (Selegiline Transdermal System) Label" (PDF). Food and Drug Administration. July 2017. Diakses tanggal 2 July 2024. 
7. ^ ^{a b c d} Lee KC, Chen JJ (November 2007). "Transdermal selegiline for the treatment of major depressive disorder". Neuropsychiatric Disease and Treatment. 3 (5): 527–537. doi:10.2147/ndt.s12160200  (tidak aktif July 6, 2024). PMC 2656289 . PMID 19300583. 
8. ^ Magyar K (2011). "The Pharmacology of Selegiline". Dalam Youdim M, Riederer P. Monoamine Oxidases and Their Inhibitors. International Review of Neurobiology. 100. Academic Press. hlm. 65–84. doi:10.1016/B978-0-12-386467-3.00004-2. ISBN 978-0-12-386467-3. PMID 21971003. 
9. ^ ^{a b c} Pae CU, Lim HK, Han C, Neena A, Lee C, Patkar AA (August 2007). "Selegiline transdermal system: current awareness and promise". Prog Neuropsychopharmacol Biol Psychiatry. 31 (6): 1153–1163. doi:10.1016/j.pnpbp.2007.04.020. PMID 17614182. 
10. ^ Löhle M, Storch A (November 2008). "Orally disintegrating selegiline for the treatment of Parkinson's disease". Expert Opin Pharmacother. 9 (16): 2881–2891. doi:10.1517/14656566.9.16.2881. PMID 18937619. 
11. ^ Clarke A, Brewer F, Johnson ES, Mallard N, Hartig F, Taylor S, Corn TH (November 2003). "A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition". Journal of Neural Transmission. 110 (11): 1241–1255. doi:10.1007/s00702-003-0036-4. PMID 14628189.  Parameter |s2cid= yang tidak diketahui akan diabaikan (bantuan)
12. ^ Rodrigues AD (June 2022). "Drug Interactions Involving 17α-Ethinylestradiol: Considerations Beyond Cytochrome P450 3A Induction and Inhibition". Clin Pharmacol Ther. 111 (6): 1212–1221. doi:10.1002/cpt.2383. PMID 34342002 Periksa nilai |pmid= (bantuan). 
13. ^ Hidestrand M, Oscarson M, Salonen JS, Nyman L, Pelkonen O, Turpeinen M, Ingelman-Sundberg M (November 2001). "CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes". Drug Metab Dispos. 29 (11): 1480–1484. PMID 11602525. 
14. ^ ^{a b} Heinonen EH, Anttila MI, Lammintausta RA (December 1994). "Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites". Clin Pharmacol Ther. 56 (6 Pt 2): 742–749. doi:10.1038/clpt.1994.204. PMID 7995016. 
15. ^ Heinonen EH, Myllylä V, Sotaniemi K, Lamintausta R, Salonen JS, Anttila M, Savijärvi M, Kotila M, Rinne UK (November 1989). "Pharmacokinetics and metabolism of selegiline". Acta Neurologica Scandinavica. Supplementum. 126: 93–99. doi:10.1111/j.1600-0404.1989.tb01788.x. PMID 2515726.  Parameter |s2cid= yang tidak diketahui akan diabaikan (bantuan)
16. ^ Chrisp P, Mammen GJ, Sorkin EM (May 1991). "Selegiline: A Review of its Pharmacology, Symptomatic Benefits and Protective Potential in Parkinson's Disease". Drugs Aging. 1 (3): 228–248. doi:10.2165/00002512-199101030-00006. PMID 1794016. 
17. ^ "4.9.1 Dopaminergik | PIO Nas". pionas.pom.go.id. Diarsipkan dari versi asli tanggal 2020-07-23. Diakses tanggal 2020-08-24. 
18. ^ Gan, Sulistia (2016). Farmakologi dan Terapi Edisi 6. Jakarta: FKUI. hlm. 211. ISBN 9789791610414.  Parameter |url-status= yang tidak diketahui akan diabaikan (bantuan)